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Abstract
Programmed cell death (apoptosis) is a complex phenomenon that is mediated in mammals mainly via the selective cleavage of
intracellular proteins by the large family of cysteine aspartate protease caspases. Apoptosis is tightly regulated by the competitive effect of
numerous proteins displaying either pro-apoptotic or anti-apoptotic activity. The ETS-family transcription factor FLI-1, frequently associated
with malignant transformation, has been shown to display anti-apoptotic activity in several cell types including avian erythroblasts, mouse
fibroblasts or lymphoid cells. We show here that apoptosis of murine preB leukemic cells is accompanied with the specific cleavage of FLI-1
by a caspase-like activity. We also demonstrate that the two isoforms of FLI-1 are indeed cleaved at three conserved sites by caspase 3 in
vitro. The conservation of these cleavage sites among species suggests that the caspase cleavage of the anti-apoptotic transcription factor FLI-
1 may represent a critical step to ensure irreversible cell death.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
The protooncogene fli-1 encodes a transcription factor
that belongs to the ets family. fli-1 implication has been
suggested in numerous oncogenic processes that occur both
in mouse and human [1]. In mouse, fli-1 transcriptional
activation resulting from proviral integration in the 5Vregion
of the fli-1 gene is a recurrent event observed in most
erythroleukemias induced by the Friend virus F-MuLV, as
well as in a significant number of leukemias induced by the
Graffi, 10A1 or Cas-Br-E retrovirus [1]. In these leukemias,
fli-1 transcriptional activation was shown to be associated
with massive overexpression of the wild-type FLI-1 protein.
Moreover, we have demonstrated that FLI-1 overexpression
is also observed in erythroleukemias induced by SFFV
proviral integration [2]. Interestingly, in this case, the
proviral integration alters the transcriptional status of
another ETS transcription factor SPI-1 that acts as a positive
regulator of the fli-1 gene. In human, the fli-1 gene is also
rearranged in a majority of cases of the Ewing family of
tumors that shares t(11,22) chromosome translocations
[1,3]. In these cases, the translocation is responsible for
the production of an abnormal fusion protein, EWS-FLI-1,
which harbors the N-terminal part of the EWS protein and
the C-terminal part of FLI-1, and that displays altered
transactivation properties compared to normal FLI-1.
Numerous studies have suggested that FLI-1 overexpres-
sion may have important impact in both proliferation and
differentiation in erythroid cells. Indeed, it has been shown
that the forced expression of FLI-1 in erythroid cells leads to
the inhibition of their terminal differentiation and to the
stimulation of their proliferation in response to erythropoie-
tin [4–6]. Other studies have shown that FLI-1 expression
may also represent a protective event against apoptosis in
different cell types. Hence, avian native erythroid progeni-
tors expressing high level of FLI-1 are more resistant to
apoptosis induced by erythropoietin withdrawal [6]. In this
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latter case, the anti-apoptotic effect of FLI-1 was shown to
be associated with the upregulation of bcl2 transcripts due to
the direct activation of the bcl2 gene promoter by FLI-1 [7].
NIH3T3 cells stably transfected with FLI-1 expression
vector were also described to be more resistant to apoptosis
than mock-tranfected cells [8]. Furthermore, transgenic mice
overexpressing FLI-1 spontaneously develop a renal auto-
immune disease that is associated with enhanced survival of
lymphoid cells [9]. Contrasting with these studies, it has
also been shown that FLI-1 overexpression in Xenopus
embryos leads to an abnormal development associated with
important modifications of cell adhesion and apoptosis [10].
However, this observed pro-apoptotic effect of FLI-1 in
Xenopus embryos may be an indirect consequence of the
important modifications of cell adhesion [10].
FLI-1 proteins are usually expressed as two distinct
isoforms of 51 and 48 kDa that differ in their N-terminal
ends as a result of alternative translation initiation of fli-1
transcripts [11,12]. The 51 and 48 kDa isoforms display
similar transactivating activities, and whether they are
involved in two different or redundant functions remains
to be investigated. In the present study, while investigating
whether these two FLI-1 isoforms were differentially
regulated during apoptosis of murine preB leukemic 70Z/
3 cells, we observed that apoptosis is associated with the
generation of new shorter FLI-1 isoforms. We further
established that these new FLI-1 isoforms were actually
products of the caspase cleavage of FLI-1. We finally
mapped the three aspartate residues of FLI-1 involved in
this cleavage. The conservation of these cleavage sites in
FLI-1 proteins among species strongly suggests that the
caspase cleavage of FLI-1 may be functionally important
in vivo.
2. Materials and methods
2.1. Cell cultures
The mouse preB cell line 70Z/3 was grown in IMDM
medium (Life Technologies) supplemented with 10% fetal
calf serum (Roche), 20 AM of a-thioglycerol (Sigma) and
penicillin – streptomycin cocktail (Life Technologies).
Apoptosis was induced by culturing the cells for 2 or 5 h
in medium containing 5 AM staurosporin (Sigma) and 5 Ag/
ml cycloheximide (Calbiochem) with or without 100 AM
ZVAD-fmk or overnight in the presence of cycloheximide
alone. Treated or untreated cells were immediately lysed in
Laemmli buffer containing the protease inhibitor cocktail
Complete (Roche).
2.2. Western blot analyses
Western blot analyses of FLI-1 proteins present in cell
lysates were performed using commercial Fli-1 antibody
(sc-356, Santa Cruz) as previously described [11].
2.3. Plasmids and in vitro transcription–translation
Plasmids, pBS Fli-1-10 mut ATG+ 100, pBS Fli-1 + 93
and pBS Fli-1-10, containing the mouse Fli-1 cDNA and
allowing the synthesis of the large, small or both FLI-1
isoforms, have been already described [11]. Mutations
allowing the change of putative aspartate cleavage sites
to asparagine were obtained from the pBS Fli-1-10
plasmid using the QuickChange site-directed mutagenesis
kit (Stratagen) and the following oligonucleotides:
GTCTGTGGTGAGTAACGATCAGTCC (D14N),
CAGTCCCTTTTTAATTCAGCATACGG (D20N), GATG-
GAGATTAACACTTCCTTCTTCC (D155N), CTTCCA-
GAACATGAATGGCAAGGAATTG (D163N ) ,
GAACAAGGAGAACTTCCTCCGAGCC (D174N),
CCTCCCATACAAACCAGTCCTCAC (D209N), GAAC-
TACTGTCCAACAGCGCCAAC (D293N). The triple
mutant D3 was obtained by introducing successively
mutations D155N and D209N in plasmid already contain-
ing mutation D20N using the same oligonucleotides. All
mutations were verified by sequencing. In vitro tran-
scription–translation was performed in the presence of
[35S]methionine from DNA templates using the TNT
Coupled Reticulocyte Lysate System (Promega) according
to the recommendations of the supplier.
2.4. In vitro cleavage of FLI-1 proteins by caspase
Active caspase-3 and -7 were from Pharmingen. In vitro
caspase cleavage was performed as already described [13].
3. Results
In standard growth conditions, the mouse preB leukemia
cell line, 70Z/3, expresses the FLI-1 protein as two already
described isoforms that migrate, respectively, at 51 and 48
kDa [11,12] (Fig. 1, lane 1). Remarkably, after treatment by
staurosporin and cycloheximide (Fig. 1, lanes 2 and 4), two
classic stimuli of the so-called intrinsic apoptotic pathway,
two additional bands migrating at about 50 and 24 kDa were
detected. These two bands, the intensity of which increased
with the duration of the apoptotic stimuli (Fig. 1, compare
lanes 2 and 4) represent the major bands observed in cells
treated overnight with cycloheximide (Fig. 1, lane 6).
Importantly, the induction of these two bands is completely
inhibited in cells treated by the caspase inhibitor ZVAD-fmk
(Fig. 1, lanes 3 and 5). These results thus indicate that
apoptosis of 70Z/3 cells is associated with specific proteol-
ysis of FLI-1 by caspase-like activity. To confirm this
possibility, we investigated whether caspases could cleave
FLI-1 in vitro. We then translated the 51 or 48 kDa FLI-1
protein using an in vitro translation system and [35S]methio-
nine labeling. Translated FLI-1 was incubated with purified
active-site-titrated caspase-3 or -7. While no cleavage was
detected in the presence of caspase-7 (data not shown),
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incubation with active caspase-3 led to a massive in vitro
cleavage of both 51 and 48 kDa isoforms of FLI-1.
Incubation of the 51 kDa FLI-1 isoform with caspase-3
led to the generation of three different cleavage products
(Fig. 2, compare lanes 1–2 and 3–4) migrating at 50, 30
and 24 kDa. Of interest, bands migrating as 50 and 24 kDa
polypeptides are similar to the ones observed in apoptotic
70Z/3 cells, hence confirming that the FLI-1 proteolysis
observed in vivo is most probably due to caspases activity.
Similarly, the 48 kDa FLI-1 isoform was also cleaved by
caspase-3 but led to only two products of 30 and 24 kDa
(Fig. 2, lanes 5 and 6). These data thus suggested the
presence of three different caspase-3 cleavage sites includ-
ing one site that is probably located in the N-terminal
specific region of the 51 kDa protein. Since incubation of
the 51 and 48 kDa FLI-1 isoforms generates exactly the
same two caspase-3 cleavage products (30 and 24 kDa), we
concluded that the latter display the same C-terminal
extremity that is common to the 51 and 48 kDa proteins.
We then mapped the different caspase sites of cleavage by
constructing mutants based on preferred P4 and P1 positions
Fig. 2. Cleavage of the large and small isoforms of mouse FLI-1 by
caspase-3 in vitro. Labeled 51 and 48 kDa, 51 kDa alone or 48 kDa alone
were translated by in vitro transcription– translation system from pBS Fli-1-
10 (lanes 1 and 2), pBS Fli-1-10 mut ATG+100 (lanes 3 and 4) or pBS Fli-
1 + 93 (lanes 5 and 6) DNA templates and incubated for 2 h with or without
caspase-3 as indicated and loaded on SDS-PAGE gels. Cleavage products
are indicated by arrows on the autoradiogram.
Fig. 3. Mapping of caspase-3 cleavage sites. (A) Experiment was performed
in the same conditions as Fig. 2. Lanes 1 and 2: WT FLI-1. Lanes 3 and 4:
FLI-1 proteins carrying mutation D20N. Lanes 5 and 6: mutation D155N.
Lanes 7 and 8: mutation D209N. (B) Lanes 1 and 2: WT FLI-1. Lanes 3 and
4: FLI-1 protein D3, carrying the three mutations D20N, D155N and
D209N. (C) Schematic diagram showing the positions of identified
cleavage sites with respect of conserved domains of FLI-1. Black box
represents the ETS DNA binding domain whereas hatched box represents
the pointed domain that is part of the N-terminal transactivating domain.
Fig. 1. Western bot analysis of FLI-1 proteins in apoptotic 70Z/3 preB cells.
Cells were treated for 2 h (lanes 2 and 3) or 5 h (lanes 4 and 5) with 5 AM
staurosporin and 5 Ag/ml cycloheximide or overnight (lane 6) with 5 Ag/ml
cycloheximide without staurosporin. Lane 1: control untreated cells. Lanes
3 and 5: treated cells in the presence of 100 AM of ZVAD-fmk. Putative
cleavage products of FLI-1 are indicated by arrows.
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[14] and on the apparent relative sizes of the in vitro
cleavage products. Mutation of Asp. 20, 155 or 209 to
Asn in the 51 kDa FLI-1 isoform were shown to block,
respectively, the generation of the 50, 30 and 24 kDa
cleavage products (Fig. 3A). Moreover, we observed that
the triple mutant D20N D155N D209N of FLI-1 (D3
mutant) was no longer cleaved in vitro by caspase-3, thus
confirming that FLI-1 is specifically cleaved by caspases in
three sites with, respectively, SLFD, MEID, SHTD non-
canonical consensus sequences (Fig. 3B).
4. Discussion
In the present study, we show that the mouse FLI-1
proteins are submitted to specific proteolysis during apop-
tosis induced in the mouse preB cell line 70Z/3. Several
evidences strongly suggest that this specific proteolysis is
due to the cleavage of FLI-1 by caspases: (i) the generation
of the two cleavage products (i.e. 50 and 24 kDa) is
abolished by the caspase inhibitor ZVAD-fmk; (ii) the
similar cleavage products are observed after incubation of
recombinant FLI-1 proteins with active caspase 3 in vitro;
(iii) these two cleavage products are not observed after
mutation of the two specific aspartate residues D20 and
D209. Intriguingly, a third caspase-3 site (D155) is also
detected in vitro but not in vivo. Since the corresponding
cleavage product (i.e. 30 kDa) includes the C-terminal part
of the protein recognized by the FLI-1 antibody used in this
study, we suggest that either D155 is not cleaved in vivo or
most probably leads to a highly unstable cleavage product.
At least two of these three cleavage sites identified in the
mouse FLI-1 protein are also present in Human, Quail,
Xenopus and Zebra fish. The only two exceptions concern
D20 that is not present in Zebra fish and D209 that is not
present in Quail, whereas D155 is conserved in all species.
The high conservation of these cleavage sites strongly
suggests that caspase cleavage of FLI-1 may be functionally
important in vivo.
A growing number of studies indicate that in addition to
structural proteins, many regulating proteins, including
transcription factors, which display anti-apoptotic activity,
are also cleaved by caspases in cells undergoing apoptosis.
In most studied cases [15–18], caspase cleavage of these
anti-apoptotic transcription factors leads to their irreversible
inactivation, which in turn is supposed to contribute to the
irreversible cell suicide. By analogy, it is tempting to
speculate that caspase cleavage of FLI-1 is involved in
the irreversible and negative regulation of its anti-apoptotic
activity. Apoptosis is known to play a crucial role in the
negative selection of lymphoid cells directed against self-
antigens [19]. Since lymphoid cells express high levels of
FLI-1, it would be then very attractive to consider that
caspase cleavage of FLI-1 might represent a conserved
mechanism that ensures irreversible cell suicide as a
mechanism for limiting auto-immune diseases [20]. Two
nonmutually exclusive mechanisms could explain the irre-
versible inactivation of FLI-1 following caspase cleavage.
One mechanism may be due to the simple reduction of the
total amount of FLI-1 proteins due to the generation of
highly unstable cleavage product as it is suspected for the
30 kDa fragment that is observed in vitro but not in vivo. If
true, this mechanism should be very progressive since, at
least during apoptosis of 70Z/3 cells, a significative reduc-
tion of the total amount of FLI-1 protein is only observed a
while after the initiation of caspases activation (Fig. 1,
compare lanes 1 and 6). Alternatively, as a second mech-
anism, the 24 kDa cleavage product that lacks the N-
terminal transactivating domain, or even the 50 kDa
cleavage product lacking the first 20 N-terminal amino
acids, might act as dominant negative proteins in the
activation of critical anti-apoptotic target genes by the wild
type 51 kDa FLI-1 isoform. Interestingly, the present study
also indicates that the 48 kDa isoform is less sensitive to
caspase cleavage than the 51 kDa isoform (compare lanes 1
and 6 in Fig. 1 and compare lanes 1 and 2 in Fig. 2). Since
we [11] and others [12] reported the existence of a specific
fli-1 transcript encoding only this 48 kDa isoform, this
raises in turn the intriguing possibility that further fine
tuning of apoptosis could also occur through the control of
the relative production of the wild type 51 and 48 kDa
isoforms.
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